1.) Ringberg A, Nordgren H, Thorstensson S, Idvall I, Garmo H, Granstrand B, Arnesson LG, Sandelin K, Wallgren A, Anderson H, Emdin S, Holmberg L:
Histopathological risk factors for ipsilateral breast events after breast conserving treatment for ductal carcinoma in situ of the breast--results from the Swedish randomised trial.
Eur J Cancer. 2007 Jan;43(2):291-8.
Department of Plastic Surgery, Malmö University Hospital, Malmö, Sweden.

2.) Wai, E. S. et al.:
Effect of radiotherapy boost and hypofractionation on outcomes in ductal carcinoma in situ.
Cancer 2011,117(1):54-62

3.) Wapnir IL, Dignam JJ, Fisher B, et al:
Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.
J Natl Cancer Inst 2011;103:478-488,

4.) Wärnberg F, Garmo H, Emdin S, et al:
Effect of radiotherapy after breast conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial.
J Clin Oncol 2014;32:3613-3618

5.) Donker M, Liti `ere S, Werutsky G, et al:
Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ:
15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial.
J Clin Oncol 2013;31:4054-4059

6.) Cuzick J, Sestak I, Pinder SE, et al:
Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ:
Long-term results from the UK/ANZ DCIS trial.
Lancet Oncol 2011;12:21-29

7.) McCormick B, Winter K, Hudis C, et al:
RTOG 9804: A prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation.
J Clin Oncol 2015;33:709-715

8.) Silverstein MJ, Lagios MD:
Choosing treatment for patients with ductal carcinoma in situ: Fine tuning the University of Southern California/Van Nuys Prognostic Index.
J Natl Cancer Inst Monogr 2010:193-1962010

9.) Silverstein MJ, Lagios MD, Craig PH, et al:
A prognostic index for ductal carcinoma in situ of the breast.
Cancer 1996;77:2267-2274

10.) Rudloff U, Jacks LM, Goldberg JI, et al:
Nomogram for predicting the risk of local recurrence after breast conserving surgery for ductal carcinoma in situ.
J Clin Oncol 2010;28:3762-3769

11.) MacAusland SG, Hepel JT, Chong FK, et al:
An attempt to independently verify the utility of the Van Nuys Prognostic Index for ductal carcinoma in situ.
Cancer 2007 ;110:2648-2653

12.) Yi M, Meric-Bernstam F, Kuerer HM, et al:
Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision.
J Clin Oncol 2012;30:600-607

13.) Wong JS, Chen Y-H, Gadd MA, et al.:
Eight-year update of a prospective study of wide excision alone for small low- or intermediate-grade ductal carcinoma in situ (DCIS).
Breast Cancer Res Treat 2014;143:343-350

14.) Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF):
Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms,
Langversion 5.02, 2025, AWMF-Registernummer: 032-045OL
http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/
Zugriff am 19.07.2025

15.) Macdonald HR, Silverstein MJ, Lee LA, Ye W, Sanghavi P, Holmes DR, et al.:
Margin width as the sole determinant of local recurrence after breast conservation in patients with ductal carcinoma in situ of the breast.
Am J Surg. 2006;192:420-2.
https://www.ncbi.nlm.nih.gov/pubmed/16978941

16.) Stuart KE, Houssami N, Taylor R, Hayen A, Boyages J:
Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta-regression analysis.
BMC Cancer. 2015;15:890.
https://www.ncbi.nlm.nih.gov/pubmed/26555555